Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 381; no. 26; pp. 2506 - 2518
Main Authors de Wit, Ronald, de Bono, Johann, Sternberg, Cora N, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Kramer, Gero, Eymard, Jean-Christophe, Bamias, Aristotelis, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, Castellano, Daniel
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 26.12.2019
Subjects
Aged
Aged, 80 and over
Analgesics
Androgen Antagonists - administration & dosage
Androgen Antagonists - adverse effects
Androgens
Androstenes - administration & dosage
Androstenes - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Castration
Colony-stimulating factor
Death
Granulocyte colony-stimulating factor
Humans
Infusions, Intravenous
Kaplan-Meier Estimate
Leukocytes (granulocytic)
Male
Metastases
Metastasis
Middle Aged
Pain
Patients
Phenylthiohydantoin - administration & dosage
Phenylthiohydantoin - adverse effects
Phenylthiohydantoin - analogs & derivatives
Prednisone
Prednisone - administration & dosage
Progression-Free Survival
Prostate cancer
Prostate-specific antigen
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - mortality
Safety
Survival
Taxoids - administration & dosage
Taxoids - adverse effects
Working groups
Online AccessGet full text

Cover

More Information
Summary:A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA response.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1911206